Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Reversible cysteine protease inhibitors show promise for a Chagas disease cure.

Ndao M, Beaulieu C, Black WC, Isabel E, Vasquez-Camargo F, Nath-Chowdhury M, Massé F, Mellon C, Methot N, Nicoll-Griffith DA.

Antimicrob Agents Chemother. 2014;58(2):1167-78. doi: 10.1128/AAC.01855-13. Epub 2013 Dec 9.

2.

Trisubstituted ureas as potent and selective mPGES-1 inhibitors.

Chiasson JF, Boulet L, Brideau C, Chau A, Claveau D, Côté B, Ethier D, Giroux A, Guay J, Guiral S, Mancini J, Massé F, Méthot N, Riendeau D, Roy P, Rubin J, Xu D, Yu H, Ducharme Y, Friesen RW.

Bioorg Med Chem Lett. 2011 Mar 1;21(5):1488-92. doi: 10.1016/j.bmcl.2011.01.006. Epub 2011 Jan 13.

PMID:
21295979
3.

Identification of potent and reversible cruzipain inhibitors for the treatment of Chagas disease.

Beaulieu C, Isabel E, Fortier A, Massé F, Mellon C, Méthot N, Ndao M, Nicoll-Griffith D, Lee D, Park H, Black WC.

Bioorg Med Chem Lett. 2010 Dec 15;20(24):7444-9. doi: 10.1016/j.bmcl.2010.10.015. Epub 2010 Oct 12.

PMID:
21041084
4.

Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors.

Giroux A, Boulet L, Brideau C, Chau A, Claveau D, Côté B, Ethier D, Frenette R, Gagnon M, Guay J, Guiral S, Mancini J, Martins E, Massé F, Méthot N, Riendeau D, Rubin J, Xu D, Yu H, Ducharme Y, Friesen RW.

Bioorg Med Chem Lett. 2009 Oct 15;19(20):5837-41. doi: 10.1016/j.bmcl.2009.08.085. Epub 2009 Aug 28.

PMID:
19748780
5.

Design and synthesis of dipeptidyl nitriles as potent, selective, and reversible inhibitors of cathepsin C.

Guay D, Beaulieu C, Truchon JF, Jagadeeswar Reddy T, Zamboni R, Bayly CI, Methot N, Rubin J, Ethier D, David Percival M.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5392-6. doi: 10.1016/j.bmcl.2009.07.114. Epub 2009 Jul 28. Erratum in: Bioorg Med Chem Lett. 2009 Nov 15;19(22):6481. Bioorg Med Chem Lett. 2010 Feb 15;20(4):1463. Truchon, Jean-Francois [added]; Bayly, Christopher I [added].

PMID:
19665376
6.

MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation.

Xu D, Rowland SE, Clark P, Giroux A, Côté B, Guiral S, Salem M, Ducharme Y, Friesen RW, Méthot N, Mancini J, Audoly L, Riendeau D.

J Pharmacol Exp Ther. 2008 Sep;326(3):754-63. doi: 10.1124/jpet.108.138776. Epub 2008 Jun 4.

PMID:
18524979
7.

In vivo inhibition of serine protease processing requires a high fractional inhibition of cathepsin C.

Méthot N, Guay D, Rubin J, Ethier D, Ortega K, Wong S, Normandin D, Beaulieu C, Reddy TJ, Riendeau D, Percival MD.

Mol Pharmacol. 2008 Jun;73(6):1857-65. doi: 10.1124/mol.108.045682. Epub 2008 Mar 6.

PMID:
18326050
8.

Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors.

Côté B, Boulet L, Brideau C, Claveau D, Ethier D, Frenette R, Gagnon M, Giroux A, Guay J, Guiral S, Mancini J, Martins E, Massé F, Méthot N, Riendeau D, Rubin J, Xu D, Yu H, Ducharme Y, Friesen RW.

Bioorg Med Chem Lett. 2007 Dec 15;17(24):6816-20. Epub 2007 Oct 17.

PMID:
18029174
9.

Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.

Méthot N, Rubin J, Guay D, Beaulieu C, Ethier D, Reddy TJ, Riendeau D, Percival MD.

J Biol Chem. 2007 Jul 20;282(29):20836-46. Epub 2007 May 29.

10.

Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886.

Riendeau D, Aspiotis R, Ethier D, Gareau Y, Grimm EL, Guay J, Guiral S, Juteau H, Mancini JA, Méthot N, Rubin J, Friesen RW.

Bioorg Med Chem Lett. 2005 Jul 15;15(14):3352-5.

PMID:
15953724
11.

A caspase active site probe reveals high fractional inhibition needed to block DNA fragmentation.

Méthot N, Vaillancourt JP, Huang J, Colucci J, Han Y, Ménard S, Zamboni R, Toulmond S, Nicholson DW, Roy S.

J Biol Chem. 2004 Jul 2;279(27):27905-14. Epub 2004 Apr 5.

12.

Deletion of microsomal prostaglandin E2 (PGE2) synthase-1 reduces inducible and basal PGE2 production and alters the gastric prostanoid profile.

Boulet L, Ouellet M, Bateman KP, Ethier D, Percival MD, Riendeau D, Mancini JA, Méthot N.

J Biol Chem. 2004 May 28;279(22):23229-37. Epub 2004 Mar 11.

13.

Differential efficacy of caspase inhibitors on apoptosis markers during sepsis in rats and implication for fractional inhibition requirements for therapeutics.

Méthot N, Huang J, Coulombe N, Vaillancourt JP, Rasper D, Tam J, Han Y, Colucci J, Zamboni R, Xanthoudakis S, Toulmond S, Nicholson DW, Roy S.

J Exp Med. 2004 Jan 19;199(2):199-207. Epub 2004 Jan 12.

14.

Structure of the pore-forming transmembrane domain of a ligand-gated ion channel.

Méthot N, Ritchie BD, Blanton MP, Baenziger JE.

J Biol Chem. 2001 Jun 29;276(26):23726-32. Epub 2001 Apr 27.

15.

An absolute requirement for Cubitus interruptus in Hedgehog signaling.

Méthot N, Basler K.

Development. 2001 Mar;128(5):733-42.

18.

Characterization of transgenic mice with targeted disruption of the catalytic domain of the double-stranded RNA-dependent protein kinase, PKR.

Abraham N, Stojdl DF, Duncan PI, Méthot N, Ishii T, Dubé M, Vanderhyden BC, Atkins HL, Gray DA, McBurney MW, Koromilas AE, Brown EG, Sonenberg N, Bell JC.

J Biol Chem. 1999 Feb 26;274(9):5953-62.

19.

The murine PKR tumor suppressor gene is rearranged in a lymphocytic leukemia.

Abraham N, Jaramillo ML, Duncan PI, Méthot N, Icely PL, Stojdl DF, Barber GN, Bell JC.

Exp Cell Res. 1998 Nov 1;244(2):394-404.

PMID:
9806790
22.
27.
28.

Supplemental Content

Loading ...
Support Center